Firm News
Wiggin and Dana Represented XCath in its Recently Announced Series C Funding Round
Wiggin and Dana represented XCath, a leader in neuro‑endovascular surgical robotics, in its recently announced $30 Million Series C funding round. This funding was led by Crescent Enterprises and Dr. Fred Moll. This investment strengthens XCath’s ability to advance life‑saving robotic technologies that expand global access to high‑quality neurovascular care.
The Wiggin and Dana deal team consisted of Evan Kipperman, R.J. Kornhaas, and Courtney Suggs.
To learn more, click here.